Georgina Long
Georgina Long is an Australian oncologist, clinical trialist, and translational researcher specialising in melanoma drug therapy development.

Georgina Venetia Long is an Australian oncologist and translational researcher working in drug therapy development. She was the first Australian and first woman named president of the US-based Society for Melanoma Research.
Growing up in Sydney's inner west with five siblings, Long also lived in America and Europe as a child. She completed high school at Santa Sabina College in 1988.
Long studied science and law at the University of Sydney before graduating with a double major in chemistry and pure maths in 1993. She earned a PhD in organic chemistry from the same university in 1996.
After working as a Fulbright Fellow at the Scripps Research Institute in California, she returned to Australia. She graduated with an MBBS in 2001.
As a medical oncologist specialising in melanoma, Long has led numerous clinical trials regarding immuno-oncology and targeted therapies. She serves as the Director of the Melanoma Institute Australia.
Long and pathologist Richard Scolyer pioneered immunotherapy use for melanoma. Long adapted these treatments for brain cancer when Scolyer was diagnosed in June 2023, making him the first brain cancer patient globally to receive pre-surgery combination immunotherapy.
In 2020, Long was appointed an Officer of the Order of Australia. She was elected a Fellow of the Australian Academy of Science in June 2024.
Long was the joint recipient of the 2024 Australian of the Year Award. In December 2024, she was included on the BBC's 100 Women list.
Key facts
- Georgina Long is the Director of the Melanoma Institute Australia.
- She was the first woman and first Australian president of the Society for Melanoma Research.
- Long was a joint recipient of the 2024 Australian of the Year Award.
- She was appointed an Officer of the Order of Australia in 2020.